GSK - GlaxoSmithKline plc
| Previous Close | 41.24 |
| Open | 41.21 |
| Bid | 41.2600 x 1100 |
| Ask | 41.2800 x 2900 |
| Day's Range | 41.22 - 41.30 |
| 52 Week Range | 35.78 - 42.36 |
| Volume | 284,732 |
| Avg. Volume | 3,791,777 |
| Market Cap | 101.917B |
| Beta (3Y Monthly) | 0.55 |
| PE Ratio (TTM) | 41.61 |
| EPS (TTM) | 0.9920 |
| Earnings Date | Feb 1, 2017 - Feb 6, 2017 |
| Forward Dividend & Yield | 2.39 (5.84%) |
| Ex-Dividend Date | 2018-11-15 |
| 1y Target Est | 43.84 |
- Market Realist•20 hours ago
What Analysts Are Recommending for Teva Pharmaceutical This Month
Is Teva Pharmaceutical an Attractive Pick This February?Stock price movementsOn February 15, Teva Pharmaceutical (TEVA) closed at $17.98, 4.05% higher than its previous closing price, 23.24% higher than its 52-week low of $14.59, and 30.74% lower
- Moody's•4 days ago
Innoviva, Inc. -- Moody's announces completion of a periodic review of ratings of Innoviva, Inc.
Announcement: Moody's announces completion of a periodic review of ratings of Innoviva, Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Innoviva, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- Market Realist•4 days ago
What Are the Key Growth Drivers for GlaxoSmithKline in 2019?
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Growth drivers On its fourth-quarter earnings conference call, GlaxoSmithKline (GSK) highlighted the prioritization of R&D (research and development)
- Zacks•4 days ago
Top Ranked Growth Stocks to Buy for February 15th
Top Ranked Growth Stocks to Buy for February 15th
Market Realist•4 days agoComparing Dividends and Tax Rates for MRK and GSK in 2019
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Dividend projectionsMerck & Co. (MRK) and GlaxoSmithKline (GSK) reported dividends per share of $1.99 and $2.08, respectively, in 2018.Analysts expect
- Market Realist•4 days ago
Merck or GlaxoSmithKline: Which Is Controlling Expenses Better?
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Expenses guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for a low- to mid-single-digit YoY (year-over-year) rise
- Zacks•5 days ago
Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B
Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
- Zacks•5 days ago
Zoetis (ZTS) Beats on Q4 Earnings & Sales, Shares Up
Zoetis (ZTS) exceeds both earnings and sales expectations in the fourth quarter of 2018.
- Market Realist•5 days ago
MRK or GSK: Which Is Expected to Report Faster EPS Growth?
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)EPS guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for non-GAAP (generally accepted accounting principles) EPS
- Market Realist•5 days ago
Is MRK or GSK Expected to Report Faster Revenue Growth in 2019?
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Revenue guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for revenue of $43.2 billion–$44.7 billion, a YoY
- Market Realist•5 days ago
What Analysts Recommend for Merck and GlaxoSmithKline This Month
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?Share price movements On February 11, Merck & Co. (MRK) closed at $76.71, 1.04% lower than its previous closing price, 45.20% higher than its 52-week low of $52.83, and 4.34% lower
- Zacks•5 days ago
AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales
AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
- Zacks•5 days ago
Top Ranked Income Stocks to Buy for February 14th
Top Ranked Income Stocks to Buy for February 14th
- Zacks•7 days ago
Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer
Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
- Thomson Reuters StreetEvents•6 days ago
Edited Transcript of GSK.L earnings conference call or presentation 6-Feb-19 2:00pm GMT
Q4 2018 GlaxoSmithKline PLC Earnings Call
- Reuters•7 days ago
Mylan launches Advair generic at one-third price
The treatment, the first generic of Advair, is approved in three doses and will be priced between $93.71 and $153.14, the company said. Advair targets certain patients with asthma or chronic obstructive pulmonary disease and brought in revenue of about $4.19 billion in 2017 for the London-listed GSK. Mylan received approval for the treatment from the U.S. Food and Drug Administration last month.
- Zacks•11 days ago
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs
Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
- InvestorPlace•12 days ago
5 Undervalued Stocks to Invest In
Overall, the stock market has made a huge improvement at the start of 2019 from where it ended in 2018; it has been a complete turnaround from last year's drop when markets entered bear market territory. But even though many stocks have completely erased all of their losses and made it back into the green, not all stocks have had this luxury. What this means is that while there are still plenty of duds out there, there are also a few undervalued stocks to buy … it has just become a little trickier to find them amid all the flashy comeback stories.To find the best stocks to invest in now, disciplined investors might start with their own watch list, which should contain "wish list" stocks that are usually too expensive or have been put there to be on the backburner for later. Among such stocks, companies that got left out of the rally are the most compelling. Even better, the best undervalued stocks to invest in are those that dropped by double-digit percentages during the current rally.Why is that?InvestorPlace - Stock Market News, Stock Advice & Trading TipsMarkets that are pricing in the negative news typically lower the risk for investors. Such companies may work to resolve the business problem at hand, which improves its prospects and leads to a higher share price in the long run. As long as the bad news reported is a temporary setback and the business model is not broken, the risks behind buying a stock on a dip are lower. * 10 Monster Growth Stocks to Buy for 2019 and Beyond With all of that in mind, here are five undervalued stocks to invest in that aren't as scary as they seem.Source: Dalvenjah via Flickr Sony (SNE)Investors expected more from Sony's (NYSE:SNE) earnings report when the company posted results on Feb. 1. Revenue of 2.4 trillion yen in the third-quarter missed estimates for 2.67 trillion yen.Adding salt to the wound, many SNE investors are fretting over Sony's weaker sales outlook, with smartphone and camera sales lagging. On the flipside, the PlayStation 4 business still could rebound. Even though the console cycle is many years old, customers will continue to buy new game titles. And in the smartphone space, a refresh in the second half of this year may give customers a reason to buy a new Sony device again.Sony is clearly not a broken company, so the stock's drop from $50 on Feb. 1 to $46.29 appears overdone. At just 4% above its yearly lows and a whopping 24% below its 52-week high, which SNE set just a few months ago, Sony stock clearly deserves its spot among the best undervalued stocks to consider now.Source: Shutterstock Celestica (CLS)Celestica (NYSE:CLS) reported fourth-quarter revenue of $1.73 billion, up 10% from last year. Net earnings rose $46.5 million to $60.1 million, bringing in earnings of 44 cents a share. However, investors were unimpressed with the weak sequential revenue in its Communications, ATS and CCS segments, which were either flat or down. Still, revenue from all segments grew in the double digits from last year.Celestica ended the year with $422 million in cash and cash equivalents. Net cash fell $335 million for the year. And the balance sheet is not as strong as it could be, with non-IFRS debt leverage at 2.6X.The company supplies equipment in ATS -- aerospace and defense, industrial, smart energy, health tech and capital equipment. Its enterprise unit consists of servers and storage. Why then, should investors believe the company will offset the weakness it faces in the eroding semiconductor market?Celestica is cutting costs in operations to align the business with the lower revenue. It will continue to build its capital equipment business. Management believes the fundamentals in this space will only improve in the long run. As next-generation adoption in display continues, its OLED business, for example, will add to its bottom line. * 7 Semiconductor Stocks to Watch After falling 16% in the last week, Celestica stock is an undervalued play worth considering.Source: Everjean via Flickr Allergan (AGN)Generic drug supplier Allergan (NYSE:AGN) recently fell 12.8% for two reasons. First, its fourth-quarter earnings report did not please investors. Earnings-per-share came in at $4.29 (non-GAAP) while revenue fell 5.8% to $4.08 billion. With GAAP down $12.83 a share, its big difference from non-GAAP is scaring off investors. Allergan's accounting does not show any transparency in the health of the business.On Friday, Feb. 1, the Food and Drug Administration approved Evolus' (NASDAQ:EOLS) Jeuveau. This product competes directly with Allergan's Botox. Pricing could come in at 20% below that of Botox, putting pressure on Allergan's bottom line.Be warned: it's likely that AGN stock will continue to sell off as investors price in the worst case scenario for Botox. Even though management already expects some pricing erosion, it is confident that the sales volume will taper off slowly. But this is good news for iinvestors in search of a bargain, as the more the stock falls, the more discount value investors get on AGN stock.As Allergan launches new products this year, it will offset the negative impact of generic drug competition for Botox, making it an undervalued stock to watch.Source: Shutterstock Innoviva (INVA)Innoviva (NASDAQ:INVA) is another stock in the drug space whose 17.5% weekly drop appears greatly overdone. The market all but erased the powerful uptrend in the stock that began after INVA sold off in November 2018 and bottomed at $14.The FDA approved Mylan's (NASDAQ:MYL) generic version of Advair, which GlaxoSmithKline (NYSE:GSK) produces. This forced investors to worry about Innoviva's prospects because the company is paid royalties from Glaxo. In the third quarter, Innova received $65.1 million in royalty revenues from Glaxo; $51.7 million came from global net sales of Revar/Breo Ellipta.On Feb. 6, Innoviva reported revenue of $79.86 million, up 14.9% from last year. With the stock trading at a forward price-to-earnings ratio of 7.6, the price-earnings-to-growth ratio is 0.55. As such, this general pessimism has created an appealing entry point to INVA stock. * 10 Dividend Growth Stocks You Can't Miss Investors appear to be overreacting to the generic competition. If demand for Innoviva's formulation does not drop and prices hold, royalty revenues should not fall as much as markets think, which makes INVA an ideal undervalued stock to invest in now.Source: Shutterstock Vodafone (VOD)Telecom stocks are out of favor. Just look at Verizon (NYSE:VZ), which is down 12% from its yearly highs; AT&T (NYSE:T) is down 24% from its highs. But Vodafone (NASDAQ: VOD) is down the most, falling 43% from its 52-week highs.Third-quarter results for VOD missed analyst consensus sales forecasts. Vodafone continued to under-perform in Europe, due to rising competition. Although the company highlighted improving customer trends in Italy, Germany, and reduced churn in Spain, this was not enough to prevent revenue falling 5.6% in Europe and 6.8% overall.With all that bad news, it is little wonder why the stock has been marching lower. But VOD still has ways to mend the wound. The company could trim the dividend and re-allocate its resources toward advertising and capital expenditures. That would put it in a better position to compete with its European counterparts. And the stock would respond if those efforts lead to better revenue numbers.Vodafone shares pay a dividend yield in excess of 6%. This is higher than Verizon's 4.45% dividend yield but almost a point below AT&T's 6.8% rate. If Vodafone grows its U.K. business as it signs on users to its 5G services and cuts costs as it signs on more customers, VOD stock will finally move higher.As of this writing, Chris Lau owned shares of Innoviva. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks That Won Super Bowl Sunday * 7 High-Yield ETFs for Brave Investors * 10 F-Rated Stocks That Could Break Your Portfolio Compare Brokers The post 5 Undervalued Stocks to Invest In appeared first on InvestorPlace.
- Zacks•12 days ago
Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19
Glaxo (GSK) beats earnings and sales estimates in the fourth quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic will severely impact the drug's U.S. sales.
- The Wall Street Journal•13 days ago
[$$] Glaxo Focuses on Cancer Drugs to Restock Pipeline
GlaxoSmithKline PLC said it expects profit to fall this year as it boosts spending on developing new cancer drugs and faces generic competition for its best-selling inhaler product for the first time. The British pharmaceutical giant on Wednesday reported upbeat full-year earnings but warned that adjusted earnings per share—a measure closely watched by analysts—could fall by 5% to 9% in 2019. Glaxo, under pressure from investors to replenish its pipeline, is determined to bolster its presence in the competitive cancer market, focusing on drugs designed to aid the body’s immune response to tumors.
- Investor's Business Daily•13 days ago
This Top Pharma Stock Undercut A Buy Point On Its Earnings Lag
Eli Lilly stock undercut a buy point Wednesday after fourth-quarter earnings lagged estimates. But shares of fellow drug giant GlaxoSmithKline stock popped on its quarterly sales beat.
Motley Fool•13 days agoGlaxoSmithKline plc (GSK) Q4 2018 Earnings Conference Call Transcript
GSK earnings call for the period ending December 31, 2018.
